Filings
| Filing | Date | Type | Filed with |
|---|
| Avecho presents at BIO-Europe | Nov 15, 2026 | Operations update | ASX |
|---|
| September 2026 Quarterly Activities Report & Appendix 4C | Oct 27, 2026 | Quarterly report | ASX |
|---|
| September 2026 Quarterly Activities Report & Appendix 4C | Oct 27, 2026 | Quarterly report | ASX |
|---|
| Change of Chief Financial Officer | Oct 27, 2026 | Other filings | ASX |
|---|
| Response to ASX Price Query | Oct 21, 2026 | Explanation request | ASX |
|---|
| Response to ASX Price Query | Oct 21, 2026 | Explanation request | ASX |
|---|
| Avecho to present at the Canaccord Drug and Device Confe | Oct 12, 2026 | Other filings | ASX |
|---|
| Avecho to present at the ASX SMIDcaps Conference | Sep 22, 2026 | Other filings | ASX |
|---|
| Avecho enters final stage of Phase III insomnia trial | Aug 30, 2026 | Operations update | ASX |
|---|
| Appendix 4D and Half-year Financial Report | Aug 25, 2026 | Interim report | ASX |
|---|
| Avecho strengthens BD capability with senior appointment | Aug 23, 2026 | Management or board change | ASX |
|---|
| Small Holding Share Sale Facility Completion | Aug 11, 2026 | Other filings | ASX |
|---|
| Japanese patent granted for CBD capsule | Aug 2, 2026 | Operations update | ASX |
|---|
| June 2026 Quarterly Activities Report & Appendix 4C | Jul 28, 2026 | Quarterly report | ASX |
|---|
| Positive interim results from Phase III insomnia program | Jun 23, 2026 | Results | ASX |
|---|
| Receipt of Research & Development Tax Incentive | May 21, 2026 | Financing | ASX |
|---|
| Avecho completes treatment for Phase III interim analysis | May 20, 2026 | Operations update | ASX |
|---|
| Expiry of Listed Options | May 12, 2026 | Financing | ASX |
|---|
| March 2026 Quarterly Activities Report & Appendix 4C | Apr 28, 2026 | Quarterly report | ASX |
|---|
| Avecho completes recruitment for Phase III interim analysis | Mar 1, 2026 | Operations update | ASX |
|---|
| Annual Report 31 December 2025 | Feb 27, 2026 | Annual report | ASX |
|---|
| December 2025 Quarterly Activities Report & Appendix 4C | Jan 29, 2026 | Quarterly report | ASX |
|---|
| Phase III CBD Clinical Trial Recruitment Update | Dec 17, 2025 | Operations update | ASX |
|---|
| AVE Secures US & EU Patent Allowances for CBD Soft-Gel | Dec 3, 2025 | Operations update | ASX |
|---|
| September 2025 Quarterly Activities Report & Appendix 4C | Oct 31, 2025 | Quarterly report | ASX |
|---|
| Avecho raises $2.5m via placement | Oct 22, 2025 | Financing | ASX |
|---|
| Appendix 4D and Half-year Financial Report | Aug 28, 2025 | Interim report | ASX |
|---|
| June 2025 Quarterly Activities Report & Appendix 4C | Jul 29, 2025 | Quarterly report | ASX |
|---|
| Phase III Insomnia Trial Recruitment Update | Jul 28, 2025 | Operations update | ASX |
|---|
| Receipt of R&D Tax Incentive | May 28, 2025 | Results | ASX |
|---|
| Phase III Trial Update - New Sites Commence Recruitment | May 19, 2025 | Operations update | ASX |
|---|
| March 2025 Quarterly Activities Report & Appendix 4C | Apr 30, 2025 | Quarterly report | ASX |
|---|
| Avecho receives initial US$3M upfront payment from Sandoz | Mar 27, 2025 | Other filings | ASX |
|---|
| Avecho & Sandoz Sign Deal to Develop CBD for Insomnia in AUS | Mar 2, 2025 | Acquisition or disposal | ASX |
|---|
| Trading Halt | Feb 27, 2025 | Trading halt or suspension | ASX |
|---|
| Appendix 4E - Preliminary Final Report | Feb 27, 2025 | Results | ASX |
|---|
| Response to ASX Price Query | Feb 14, 2025 | Explanation request | ASX |
|---|
| December 2024 Quarterly Activities Report & Appendix 4C | Jan 30, 2025 | Quarterly report | ASX |
|---|
| September 2024 Quarterly Activities Report & Appendix 4C | Oct 28, 2024 | Quarterly report | ASX |
|---|
| June 2024 Quarterly Activities Report & Appendix 4C | Jul 30, 2024 | Quarterly report | ASX |
|---|
| Chair's Address and CEO Presentation | May 30, 2024 | Meeting outcome | ASX |
|---|
| First Patient dosed in Phase III insomnia trial | May 15, 2024 | Operations update | ASX |
|---|
| March 2024 Quarterly Activities Report & Appendix 4C | Apr 30, 2024 | Quarterly report | ASX |
|---|
| Avecho commences Phase III insomnia trial | Mar 25, 2024 | Operations update | ASX |
|---|
| Avecho meets TGA ahead of Phase III Clinical Trial | Mar 13, 2024 | Operations update | ASX |
|---|
| AVE receives final ethics approval for Phase III CBD trial | Mar 6, 2024 | Operations update | ASX |
|---|
| Appendix 4E and Annual Report 31 December 2023 | Feb 29, 2024 | Annual report | ASX |
|---|
| December 2023 Quarterly Activities Report & Appendix 4C | Jan 30, 2024 | Quarterly report | ASX |
|---|
| September 2023 Quarterly Activities Report & Appendix 4C | Oct 30, 2023 | Quarterly report | ASX |
|---|
| Reinstatement to Official Quotation | Aug 28, 2023 | Trading halt or suspension | ASX |
|---|
| Avecho raises further $6M for Phase III trial | Aug 28, 2023 | Financing | ASX |
|---|
| Voluntary Suspension | Aug 24, 2023 | Trading halt or suspension | ASX |
|---|
| June 2023 Quarterly Activities Report & Appendix 4C | Jul 24, 2023 | Quarterly report | ASX |
|---|
| AVE CBD capsule passes two-year stability milestone | Jun 21, 2023 | Other filings | ASX |
|---|
| AVE adds TPM cannabinoid gummies to portfolio | Jun 6, 2023 | Other filings | ASX |
|---|
| USPTO allows new TPM manufacturing patent | May 28, 2023 | Other filings | ASX |
|---|
| Avecho licenses TPM for use in cancer drugs | May 22, 2023 | Other filings | ASX |
|---|
| AVE commences manufacturing for Phase III trial | May 16, 2023 | Other filings | ASX |
|---|
| Results of Entitlement Offer | May 8, 2023 | Financing | ASX |
|---|
| March 2023 Quarterly Activities Report & Appendix 4C | Apr 27, 2023 | Quarterly report | ASX |
|---|
| Investor Presentation | Apr 3, 2023 | Other filings | ASX |
|---|
| Prospectus | Apr 3, 2023 | Offer document | ASX |
|---|
| Entitlement Offer to raise $11m for Phase 3 clinical trial | Apr 3, 2023 | Financing | ASX |
|---|
| Clinical CBD program expands with the Lambert Initiative | Feb 21, 2023 | Other filings | ASX |
|---|
| December 2022 Quarterly Activities Report & Appendix 4C | Jan 30, 2023 | Quarterly report | ASX |
|---|
| Athenex submits Avechos phytonadione to FDA pre-IND | Jan 12, 2023 | Other filings | ASX |
|---|
| Avecho receives ethics approval for Phase III CBD trial | Dec 21, 2022 | Other filings | ASX |
|---|
| AVE signs development agreement with Perrigo | Dec 19, 2022 | Other filings | ASX |
|---|
| September 2022 Quarterly Activities Report & Appendix 4C | Oct 27, 2022 | Quarterly report | ASX |
|---|
| Increased CBD absorption in dogs vs commercial comparator | Sep 19, 2022 | Other filings | ASX |
|---|
| June 2022 Quarterly Activities Report & Appendix 4C | Jul 28, 2022 | Quarterly report | ASX |
|---|
| Security Class Reinstatement to Quotation- AVEO | Jul 14, 2022 | Trading halt or suspension | ASX |
|---|
| Update on Listed Options and Federal Court Application | Jul 14, 2022 | Legal or regulatory action | ASX |
|---|
| Suspension from Official Quotation - AVEO | Jun 8, 2022 | Trading halt or suspension | ASX |
|---|
| March 2022 Quarterly Activities Report & Appendix 4C | Apr 28, 2022 | Quarterly report | ASX |
|---|
| Positive results from AVEs topical CBD pain study | Mar 28, 2022 | Other filings | ASX |
|---|
| Dosing begins in topical CBD pain study | Feb 28, 2022 | Other filings | ASX |
|---|
| Appendix 4E and Annual Report 31 December 2021 | Feb 27, 2022 | Annual report | ASX |
|---|
| AVE license agreement for US recreational cannabis market | Feb 2, 2022 | Other filings | ASX |
|---|
| December 2021 Quarterly Activities Report & Appendix 4C | Jan 30, 2022 | Quarterly report | ASX |
|---|
| AVE Licenses CBD Soft-Gel to Medterra Pharma for Arthritis | Dec 20, 2021 | Other filings | ASX |
|---|
| Positive results from Avechos Phase I trial of CBD soft-gel | Dec 7, 2021 | Other filings | ASX |
|---|
| September 2021 Quarterly Activities Report & Appendix 4C | Oct 28, 2021 | Quarterly report | ASX |
|---|
| Topical CBD pain study with Lambert Initiative approved | Oct 20, 2021 | Other filings | ASX |
|---|
| Dosing begins in Phase I PK trial testing CBD soft-gel | Oct 3, 2021 | Other filings | ASX |
|---|
| Phase I clinical trial testing CBD product-enrolment begins | Sep 14, 2021 | Other filings | ASX |
|---|
| June 2021 Quarterly Activities Report & Appendix 4C | Jul 26, 2021 | Quarterly report | ASX |
|---|
| Avecho to Present New CBD Data at GCI Virtual Summit | Jun 8, 2021 | Other filings | ASX |
|---|
| Chairs Address and CEO Presentation | May 31, 2021 | Other filings | ASX |
|---|
| AB Vista to explore new TPM applications for Animal Health | May 30, 2021 | Other filings | ASX |
|---|
| TGA meeting for CBD soft-gel targeting insomnia | May 25, 2021 | Other filings | ASX |
|---|
| Avecho completes pharmaceutical CBD soft-gel product | May 20, 2021 | Other filings | ASX |
|---|
| March 2021 Quarterly Activities Report & Appendix 4C | Apr 28, 2021 | Quarterly report | ASX |
|---|
| Avecho receives ethics approval for CBD human trial | Apr 12, 2021 | Other filings | ASX |
|---|
| AVE receives firm commitment to raise $5.06 via placement | Feb 9, 2021 | Financing | ASX |
|---|
| December 2020 Quarterly Activities Report & Appendix 4C | Jan 29, 2021 | Quarterly report | ASX |
|---|
| AVE begins Human Trial on CBD product | Dec 22, 2020 | Other filings | ASX |
|---|
| Improved Propofol TPM Formulation Passes Toxicology Study | Nov 3, 2020 | Other filings | ASX |
|---|
| September 2020 Quarterly Activities Report & Appendix 4C | Oct 28, 2020 | Quarterly report | ASX |
|---|
| TPM Cannabinoid Development Program Update | Oct 18, 2020 | Other filings | ASX |
|---|
| Progress Update for TPM Cannabinoid Development Program | Aug 19, 2020 | Other filings | ASX |
|---|
| June 2020 Quarterly Activities Report & Appendix 4C | Jul 28, 2020 | Quarterly report | ASX |
|---|
| March 2020 Quarterly Activities Report & Appendix 4C | Apr 28, 2020 | Quarterly report | ASX |
|---|
| Changes to Leadership Team | Apr 26, 2020 | Other filings | ASX |
|---|
| Medicinal cannabis supply agreement with Tasmanian Alkaloids | Apr 26, 2020 | Other filings | ASX |
|---|
| Avecho signs Term Sheet for Cannabinoid Supply with Purisys | Apr 13, 2020 | Other filings | ASX |
|---|
| Appendix 4E and Annual Report 31 December 2019 | Mar 1, 2020 | Annual report | ASX |
|---|
| Appendix 4C - Quarterly | Jan 22, 2020 | Quarterly report | ASX |
|---|
| Injectable Portfolio Update - Products Differentiated by TPM | Dec 4, 2019 | Other filings | ASX |
|---|
| Terumo return rights to TPM/Propofol Injectable | Oct 16, 2019 | Other filings | ASX |
|---|
| Ashland purchases manufacturing rights for Vital ET and TPM | Jun 19, 2019 | Other filings | ASX |
|---|
| FDA meeting provides guidance for TPM/Oxymorphone patch | Jan 17, 2019 | Guidance | ASX |
|---|
| Reinstatement to Offical Quotation | Dec 18, 2018 | Other filings | ASX |
|---|
| Phosphagenics and Mylan Agree Settlement | Dec 18, 2018 | Other filings | ASX |
|---|
| Suspension from Official Quotation | Dec 11, 2018 | Trading halt or suspension | ASX |
|---|
| Phosphagenics Arbitration Award Issued | Nov 11, 2018 | Other filings | ASX |
|---|
| Phosphagenics Receives Further Arbitration Process Update | Oct 22, 2018 | Other filings | ASX |
|---|
| Phosphagenics Licensing Agreement Update | Sep 9, 2018 | Other filings | ASX |
|---|
| Half Year Accounts | Aug 13, 2018 | Interim report | ASX |
|---|
| AGM Chairmans Address and CEO Presentation | May 24, 2018 | Other filings | ASX |
|---|
| Terumo Shifts Focus From Oxymorphone Patch to Injectables | Mar 19, 2018 | Other filings | ASX |
|---|
| Preliminary Final Report | Feb 27, 2018 | Results | ASX |
|---|
| Phosphagenics Placement Secures A$1.37 million | Jan 17, 2018 | Financing | ASX |
|---|
| Phosphagenics Receipt of R&D Tax Incentive | Jan 16, 2018 | Other filings | ASX |
|---|
| Phosphagenics Announces Results of Dairy Trial | Dec 21, 2017 | Other filings | ASX |
|---|
| TPM Improves Negative Effects of Heat Stress in Poultry | Dec 14, 2017 | Other filings | ASX |
|---|
| Phosphagenics Multinational License for TPM in Personal Care | Dec 3, 2017 | Other filings | ASX |
|---|
| Phosphagenics Update on TPM/Propofol Development Program | Nov 8, 2017 | Other filings | ASX |
|---|
| Phosphagenics Entitlement Offer Information Booklet | Oct 3, 2017 | Financing | ASX |
|---|
| Phosphagenics Announces Equity Raising | Sep 26, 2017 | Other filings | ASX |
|---|
| Phosphagenics Signs Term Sheet TPM Diclofenac Gel in Asia | Sep 25, 2017 | Other filings | ASX |
|---|
| Phosphagenics Market Update - Potential Return of Capital | Sep 1, 2017 | Other filings | ASX |
|---|
| June 2017 Half-year Financial Report and Appendix 4D | Aug 31, 2017 | Interim report | ASX |
|---|
| Phosphagenics Signs Patch Development Agreement with Terumo | Aug 22, 2017 | Other filings | ASX |
|---|
| Phosphagenics Sells BioElixia Brand to Pure Beauty Australia | Aug 9, 2017 | Other filings | ASX |
|---|
| POH Mylan Arbitration Update- Expert Report on Damages Filed | May 28, 2017 | Other filings | ASX |
|---|
| Phosphagenics and IAH Cease All Partnerships | Mar 9, 2017 | Other filings | ASX |
|---|
| Appendix 4E and Annual Financial Report | Feb 28, 2017 | Annual report | ASX |
|---|
| Phosphagenics Non-Binding Term Sheet for OxyM Patch in Japan | Jan 30, 2017 | Other filings | ASX |
|---|
| Phosphagenics Poultry Feed Study Reports Positive Data | Dec 14, 2016 | Other filings | ASX |
|---|
| Reformulation TPM/Oxymorphone Complete | Dec 11, 2016 | Other filings | ASX |
|---|
| Phosphagenics ProPhase Arbitration Ruling Handed Down | Nov 16, 2016 | Other filings | ASX |
|---|
| S&P DJ Indices Announces March Quarterly Rebalance | Nov 7, 2016 | Other filings | ASX |
|---|
| Phosphagenics Updates Long Term Incentive Scheme | Sep 11, 2016 | Other filings | ASX |
|---|
| Phosphagenics Begins Feed Efficiency Study in Poultry | Aug 31, 2016 | Other filings | ASX |
|---|
| June 2016 Half-year Financial Report and Appendix 4D | Aug 25, 2016 | Interim report | ASX |
|---|
| Phosphagenics Completes Grower/Finisher Pig Study | Jun 29, 2016 | Other filings | ASX |
|---|
| Phosphagenics Initiates Cattle Study | Jun 1, 2016 | Other filings | ASX |
|---|
| Phosphagenics Expands Licence Agreement for Diclofenac Gel | May 18, 2016 | Other filings | ASX |
|---|
| Phosphagenics Expands Japanese Option to Oxycodone Patch | May 17, 2016 | Other filings | ASX |
|---|
| Phosphagenics Signs Japanese License Option and R&D Alliance | Apr 29, 2016 | Other filings | ASX |
|---|
| Successful Results -Phase 2 TPM Trentinoin Gel Study on Acne | Mar 30, 2016 | Other filings | ASX |
|---|
| June 2010 Half Yearly Appendix 4D and Financial Report | Mar 30, 2016 | Interim report | ASX |
|---|
| Appointment of Joint CEO - Dr Esra Ogru | Mar 30, 2016 | Management or board change | ASX |
|---|
| POH Global Agreement with Novartis Animal Health | Mar 30, 2016 | Other filings | ASX |
|---|
| Response to an ASX Price Query | Mar 30, 2016 | Explanation request | ASX |
|---|
| December 2009 Appendix 4E and Statutory Financial Report | Mar 30, 2016 | Results | ASX |
|---|
| Phosphagenics Launches Australian Skincare Products | Mar 30, 2016 | Other filings | ASX |
|---|
| Positive Results Phase 1B Study Transdermal Oxycodone Patch | Mar 30, 2016 | Other filings | ASX |
|---|
| Trading halt | Mar 30, 2016 | Trading halt or suspension | ASX |
|---|
| POH Ready to Commence Pivital Oxycodone Clinical Trials | Mar 30, 2016 | Other filings | ASX |
|---|
| June 2011 Half Yearly Appendix 4D and Financial Report | Mar 30, 2016 | Interim report | ASX |
|---|
| New National Stockist for ELIXIA Personal Care Product Range | Mar 30, 2016 | Other filings | ASX |
|---|
| Major Distribution Agreement for Asia for ELIXIA Products | Mar 30, 2016 | Other filings | ASX |
|---|
| Elixia range of Personal Care Products - Update | Mar 30, 2016 | Other filings | ASX |
|---|
| Launch of BodyShaper Cellulite Contour Creme | Mar 30, 2016 | Other filings | ASX |
|---|
| Phosphagenics moves into lucrative hair market | Mar 30, 2016 | Other filings | ASX |
|---|
| Equity Raising | Mar 30, 2016 | Other filings | ASX |
|---|
| Phosphagenics to Partner Agricultural Company for ANZ market | Mar 30, 2016 | Other filings | ASX |
|---|
| Appendix 4E December 2010 Preliminary Final Report | Mar 30, 2016 | Results | ASX |
|---|
| Phosphagenics collaboration to develop psoriasis drug | Mar 30, 2016 | Other filings | ASX |
|---|
| Phosphagenics Collaborates With 3M To Develop Pain Patch | Mar 30, 2016 | Other filings | ASX |
|---|
| POH: Anti-fat Peptide Patch progresses | Mar 30, 2016 | Other filings | ASX |
|---|
| Preparation- pain patch manufacturing after positive results | Mar 30, 2016 | Other filings | ASX |
|---|
| POH: Phosphagenics - Calzada - Exercise of option | Mar 30, 2016 | Other filings | ASX |
|---|
| Neura Therapeutik Appointed as US Strategic Advisors | Mar 30, 2016 | Other filings | ASX |
|---|
| POH Further Refinements to Oxycodone Patch Design | Mar 30, 2016 | Other filings | ASX |
|---|
| POH adds David Jones as retail partner for Elixia products | Mar 30, 2016 | Other filings | ASX |
|---|
| POH Signs License Agreement with Intas Pharmaceuticals | Mar 30, 2016 | Other filings | ASX |
|---|
| Korean Distribution Agreement for BioElixia | Mar 30, 2016 | Other filings | ASX |
|---|
| December 2011 Preliminary Final and Audited Financial Report | Mar 30, 2016 | Other filings | ASX |
|---|
| Pivotal TPM-oxycodone Patch Trials Begin | Mar 30, 2016 | Other filings | ASX |
|---|
| Successful $24.1m Capital Raising and $3m SPP | Mar 30, 2016 | Financing | ASX |
|---|
| Phosphagenics Pain Program Update | Mar 30, 2016 | Other filings | ASX |
|---|
| Invoicing and Accounting Misappropriations Investigation | Mar 30, 2016 | Legal or regulatory action | ASX |
|---|
| Invoicing and Accounting Irregularities | Mar 30, 2016 | Other filings | ASX |
|---|
| POH signs Agreement with Agricultural Research Service | Mar 30, 2016 | Other filings | ASX |
|---|
| TPM/Diclofenac Gel - Themis in Supply Agmt with Novartis | Mar 30, 2016 | Other filings | ASX |
|---|
| Oxymorphone Patch Meets Phase 1 End Points | Mar 30, 2016 | Other filings | ASX |
|---|
| December 2012 Appendix 4E and Audited Financial Report | Mar 30, 2016 | Results | ASX |
|---|
| Oxycodone Patch Update | Mar 30, 2016 | Other filings | ASX |
|---|
| Phosphagenics to Supply Firming Cream to GNC | Mar 30, 2016 | Other filings | ASX |
|---|
| Oxycodone Patch Update - Development and Product Expansion | Mar 30, 2016 | Other filings | ASX |
|---|
| POH in JV to Supply TPM Equine Supplements to Golbal Market | Mar 30, 2016 | Other filings | ASX |
|---|
| POH Licences TPM Platform to Indian Pharmaceutical Company | Mar 30, 2016 | Other filings | ASX |
|---|
| June 2014 App 4D Half Yearly Report and Financial Report | Mar 30, 2016 | Interim report | ASX |
|---|
| Opioid Patch Program Update | Mar 30, 2016 | Other filings | ASX |
|---|
| POH Topical Oxycodone Patch Alleviates Pain in Racehorses | Mar 30, 2016 | Other filings | ASX |
|---|
| Enrolments Completed for Phase 2 Acne Treatment Trial | Mar 30, 2016 | Other filings | ASX |
|---|
| December 2013 Appendix 4E - Annual Financial Report | Mar 30, 2016 | Annual report | ASX |
|---|
This page holds 200 of 243 filings.